CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 543 produtos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CLK1/2-IN-1
CAS:CLK1/2-IN-1 is a CLK1 and CLK2 inhibitor and it also inhibits SRPK1 and SRPK2.Fórmula:C21H20F3N7OPureza:98%Cor e Forma:SolidPeso molecular:443.42CDK1-IN-3
CDK1-IN-3 is a selective inhibitor targeting CDK1 (36.8 nM), CDK2 (305.17 nM), CDK5 (369.37 nM); used in cancer research.Fórmula:C28H25ClF3N5O2Cor e Forma:SolidPeso molecular:555.98DDO-6079
CAS:DDO-6079 is an efficient CDC37 inhibitor. It suppresses the HSP90-CDC37 and CDC37-CDK4/6 chaperone complexes by binding to an allosteric site on CDC37. Additionally, DDO-6079 reduces the thermal stability of CDK6.Fórmula:C18H13ClN2O3Cor e Forma:SolidPeso molecular:340.76Zeltociclib
CAS:Zeltociclib is an inhibitor of cyclin-dependent kinases (CDKs) with anti-tumor properties.Fórmula:C18H20F3N4O2PCor e Forma:SolidPeso molecular:412.346CDK9-IN-38
CAS:CDK9-IN-38 (compound 14) is a CDK9 inhibitor with IC50 values of 1.2 nM for wild-type CDK9 and 3.3 nM for the L156F mutant. It effectively inhibits tumor growth both in vitro and in vivo.Fórmula:C22H23N5O3SCor e Forma:SolidPeso molecular:437.515Haspin-IN-1
Haspin-IN-1 blocks haspin (IC50: 119 nM) and inhibits CLK1, DYRK1A, CDK9 with potential as an anticancer drug.Fórmula:C12H8N4O2SCor e Forma:SolidPeso molecular:272.28CDK9-IN-11
CAS:CDK9-IN-11 is a potent CDK9 inhibitor that is the ligand for the PROTAC CDK9 Degrader-1 [1].Fórmula:C20H25N3O4Pureza:98%Cor e Forma:SolidPeso molecular:371.43CDK/HDAC-IN-1
CDK/HDAC-IN-1 inhibits CDK2/4/6 & HDAC6 with IC50s: 60.9, 276, 27.2, and 128.6 nM respectively.Fórmula:C20H18N4O4Cor e Forma:SolidPeso molecular:378.38CDK9-IN-34
CAS:CDK9-IN-34 (Compound 1b) is an inhibitor of CDK9 with an IC50 of 0.25 μM. It exhibits cytotoxicity against cancer cell lines HCT116, MCF7, and K652, with IC50 values of 1.43 μM, 3.01 μM, and 50.27 μM, respectively. Additionally, CDK9-IN-34 demonstrates antiviral activity against coronavirus 229E with an IC50 of 145.92 μM.Fórmula:C18H20N4Cor e Forma:SolidPeso molecular:292.38CDK4/6-IN-24
CAS:CDK4/6-IN-24 (Compound A) is an inhibitor of CDK4/6 with broad-spectrum antitumor activity. It can effectively inhibit various cancer cells, exhibiting an IC50 in the submicromolar range.Fórmula:C32H41N7O3Cor e Forma:SolidPeso molecular:571.713CDK1-IN-7
CAS:CDK1-IN-7 (compound M7) is a potent CDK1 inhibitor. It effectively suppresses the proliferation and migration of HCT116 and Lovo cells, making it a valuable tool for colorectal cancer research.Fórmula:C23H19ClN4O3Cor e Forma:SolidPeso molecular:434.88SGC-CLK-1
CAS:SGC-CLK-1 is a potent and selective inhibitor of Cdc2-like kinases CLK1, CLK2, and CLK4. It effectively inhibits the growth of melanoma and glioblastoma cells.Fórmula:C19H15F3N6O2Cor e Forma:SolidPeso molecular:416.36CDK8-IN-11
CAS:CDK8-IN-11 is a CDK8 inhibitor that demonstrates anti-proliferative activity against colon cancer cell lines and inhibits the activation of WNT/β-catenin.Fórmula:C19H15F3N4O2Pureza:99.74%Cor e Forma:SolidPeso molecular:388.34Ref: TM-T61742
1mg54,00€5mg114,00€10mg178,00€25mg409,00€50mg708,00€100mg982,00€1mL*10mM (DMSO)126,00€PPA-037
CAS:PPA-037 is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). It induces the degradation of Cyclin K, thereby enhancing antiproliferative effects on tumor cells. PPA-037 holds potential for use in cancer research.Fórmula:C25H27N7Cor e Forma:SolidPeso molecular:425.53Cdc7-IN-19
CAS:Cdc7-IN-19 (compound 1-1) is a potent CDC7 inhibitor with an IC 50 of 1.49 nM [1].Fórmula:C19H21N5O2Cor e Forma:SolidPeso molecular:351.40CDK5-IN-2
CAS:CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor that acts on CDK5/p25 (IC50: 0.2 nM) and CDK2/CycA (IC50: 23 nM).Fórmula:C29H28FN5OCor e Forma:SolidPeso molecular:481.56CDK1-IN-5
CDK1-IN-5 is a selective inhibitor for CDK1 (IC50: 42.19 nM), CDK2, CDK5, halting cancer cell growth.Fórmula:C27H26ClN5OSCor e Forma:SolidPeso molecular:504.05CDK2-IN-31
CAS:CDK2-IN-31 (compound I-125A) is an inhibitor of CDK2 and is utilized in cancer research.Fórmula:C37H52N6O5Cor e Forma:SolidPeso molecular:660.85Protein kinase inhibitor 13
CAS:Protein kinase inhibitor 13 (Compound I-90) functions as a kinase inhibitor, specifically targeting kinases such as PIM-1, CDK-2, GSK-3, and SRC.Fórmula:C19H20FN5OSCor e Forma:SolidPeso molecular:385.458CDK12/13 ligand 1
CAS:ALK-IN-29 (compound 4c) exhibits notable inhibitory activity against tyrosine kinases such as ALK, CDK2/CyclinE1, and FAK, with the strongest inhibition observed against ALK kinase, showing a 40.63% inhibition rate at a concentration of 10 μM. ALK-IN-29 is useful for cancer research.Fórmula:C26H26BrN5OCor e Forma:SolidPeso molecular:504.42CDK9/PARP-IN-1
CAS:CDK9/PARP-IN-1 (compound 37) is an inhibitor of CDK9 and PARP. It demonstrates IC50 values of 118 nM for CDK9 and 107 nM for PARP1. This compound exhibits a broad-spectrum anti-proliferative effect across various cancer cell lines.Fórmula:C38H34F2N8O3Cor e Forma:SolidPeso molecular:688.725YKL-1-116
CAS:YKL-1-116 is an effective, selective, and covalent CDK7 inhibitor.Fórmula:C34H38N8O3Pureza:98%Cor e Forma:SolidPeso molecular:606.72Protein Kinase Inhibitor 12
CAS:Protein Kinase Inhibitor 12 (compound 1-91) is protein kinase inhibitor,PIM-1, CDK-2, GSK-3, and SRC mammalian protein kinases.Fórmula:C14H14N4OSPureza:98.06%Cor e Forma:SolidPeso molecular:286.35CDK7/12-IN-1
CAS:CDK7/12-IN-1 is a selective CDK7 (IC50: 3 nM) and CDK12 (IC50: 277 nM) inhibitor, effective against tumor growth.Fórmula:C25H34N8OCor e Forma:SolidPeso molecular:462.59Cimpuciclib tosylate
CAS:Cimpuciclib tosylate, a selective CDK4 inhibitor (IC50: 0.49 nM), exhibits anti-tumor activity.Fórmula:C37H43FN8O4SCor e Forma:SolidPeso molecular:714.85Anticancer agent 30
Anticancer agent 30 (6f-Z), a 3-arylidene-2-oxindole, selectively inhibits CDK2, showing potent anticancer potential.Fórmula:C22H15ClFNOCor e Forma:SolidPeso molecular:363.81PKMYT1-IN-7
CAS:PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC50 values of 1.6 nM for PKMYT1 and 0.06 μM for pCDK1. It inhibits the phosphorylation of CDK1 at T14 and Y15 sites and exhibits anticancer activity both in vitro and in vivo.Fórmula:C17H18FN5O3Cor e Forma:SolidPeso molecular:359.355Cdc7-IN-8
CAS:Cdc7-IN-8, inhibits Cdc7 kinase, key in DNA replication, and is promising for cancer research. (WO2021032170A1)Fórmula:C19H21N5O2Cor e Forma:SolidPeso molecular:351.40Cdc7-IN-11
CAS:Cdc7-IN-11 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in the study of proliferative diseases.Fórmula:C20H22F2N4O2SCor e Forma:SolidPeso molecular:420.48CLK1/4-IN-1
CLK1/4-IN-1 inhibits Clk1/4 (IC50: 9.7/6.6 nM), curbing T24 cell growth (GI50: 1.1 μM). Potential cancer research tool.Fórmula:C18H14ClNO4SCor e Forma:SolidPeso molecular:375.83GSK3-IN-10
CAS:GSK3-IN-10 (Compound 4) is a multi-target inhibitor primarily affecting GSK3α and GSK3β with IC50 values of 1.0 nM and 2.0 nM, respectively. It inhibits the activation of β-catenin, enhances neuronal survival, and provides protective effects against endoplasmic reticulum stress.Fórmula:C17H18F2N4O3Cor e Forma:SolidPeso molecular:364.347CDK4-IN-1
CAS:CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50Fórmula:C22H29ClN8Pureza:98%Cor e Forma:SolidPeso molecular:440.97CDK1-IN-4
CDK1-IN-4 inhibits CDK1 (IC50: 44.52 nM), CDK2/CDK5 less potently, impacts cell cycle, used in cancer studies.Fórmula:C26H24ClN5SCor e Forma:SolidPeso molecular:474.02CDK7-IN-33
CAS:CDK7-IN-33 (Compound 148) is a CDK7 inhibitor with a Ki value of 21.75 nM. It suppresses the proliferation of A549 cells expressing CDK7WT, with a pIC50 of 7.37.Fórmula:C29H36N6O4SCor e Forma:SolidPeso molecular:564.699Haspin-IN-2
CAS:Haspin-IN-2 is a potent haspin inhibitor (IC50: 50 nM) and also inhibits CLK1 (IC50: 445 nM) and DYRK1A (IC50: 917 nM).Fórmula:C12H8N4O3Cor e Forma:SolidPeso molecular:256.22Cdc7-IN-10
CAS:Cdc7-IN-10 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in studies of proliferative diseases.Fórmula:C20H22F2N4O2SCor e Forma:SolidPeso molecular:420.48DS96432529
DS96432529 is a potent and orally active bone anabolic agent through CDK8 inhibition.Fórmula:C18H26N4O3SCor e Forma:SoildPeso molecular:378.49GFB-12811
CAS:GFB-12811 is an orally active, selective, and potent CDK5 inhibitor, used in the study of autosomal dominant polycystic kidney disease.Fórmula:C22H23F4N5OPureza:98.88%Cor e Forma:SolidPeso molecular:449.44LY3143921 hydrate
CAS:LY3143921 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor with broad in vitro anticancer activity [1].Fórmula:C16H14FN5O2Pureza:98.43%Cor e Forma:SolidPeso molecular:327.31Tanuxiciclib
CAS:Tanuxiciclib is a cyclin dependent kinase (CDK) inhibitor, specifically designed to interfere with cell cycle progression by inhibiting the activity of CDKs, which are crucial regulators of cell division.Fórmula:C15H13FN6OCor e Forma:SolidPeso molecular:312.308GSK-3/CDK5/CDK2-IN-1
CAS:GSK-3/CDK5/CDK2-IN-1 is an imidazole derivative compound that inhibits cdk5, cdk2, and GSK-3.it has demonstrated applications in cancer research and the study of neurodegenerative diseases [1].Fórmula:C21H22N4O2Cor e Forma:SolidPeso molecular:362.433Tibremciclib
CAS:Tibremciclib is a cyclin-dependent kinase 4 (CDK4) inhibitor that exhibits antineoplastic properties [1].
Fórmula:C28H32F2N8Pureza:98%Cor e Forma:SolidPeso molecular:518.6YK-2168
CAS:YK-2168 is a differentiated selective inhibitor of CDK9.
Fórmula:C16H18ClN5Cor e Forma:SolidPeso molecular:315.80Ref: TM-T200769
Produto descontinuado
